Skip to main content
. 2017 Mar 8;8(15):24063–24076. doi: 10.18632/oncotarget.16030

Figure 4. Fulvestrant enhances the anti-proliferative effects of FGFR inhibitor AZD4547 in NSCLC cell lines.

Figure 4

Cells were treated with 5μM fulvestrant, 5 or 10μM AZD4547 or the combination for 72 hr. Cellular proliferation was measured using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. Cell Titer reagent (20μl) was added to each well and plates were incubated for 1 hr. Results are the mean ± S.E. of at least 3 independent experiments each with 6 samples per experimental treatment. ANOVA, * = P < .05; ** = P < .01;*** = P < .001. A. 201T; B. 273T; C. A549.